A prior study analyzing the amount of exosomal PD-L1 in stage III-IV melanoma patients before and after treatment with pembrolizumab found that higher exosomal PD-L1 levels were associated with worse clinical outcomes as T cells cannot overcome the solid inhibitory effect (Chen et al., 2018). Here, CD274 is linked to melanoma.